Gigaset AG / Key word(s): Capital Increase/Mergers & Acquisitions 27.09.2013 10:51 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. Capital increase out of authorized capital and issuance of convertible bond - backstop investor available subject to condition that investor achieves 30% of share capital - takeover bid expected Munich, September 27, 2013. Gigaset AG today resolved to increase its capital out of authorized capital and to issue convertible bonds. A backstop investor agreed to acquire all new shares and convertible bonds which remain unsubscribed after the exercise of the pre-emptive rights of existing shareholders subject to the condition that the backstop investor will obtain a minimum 30 % stake in Gigaset AG after such acquisition. Subject tothe same condition, the investor will make substantial investment into a new business segment to be established at Gigaset. The Executive Board of Gigaset AG has today, with the approval of the Supervisory Board, passed a resolution to increase the capital of the Company out of authorized capital by up to 19,571,049.00 EUR (approximately 39% of the current share capital) against contributions in cash by issuing up to 19,571,049 bearer shares of common stock without par value (no-par shares). Existing shareholders enjoy their statutory pre-emptive rights. The new shares will carry full dividend rights as of January 1, 2013. The offer price for the new shares will be 1.00 EUR each and subscription ratio will be 23:9. The Company will not arrange for subscription rights trading. The Executive Board of Gigaset AG has today, with the approval of the Supervisory Board, passed a resolution to issue convertible bonds in the aggregate principal amount of 23,340,289.00 EUR. Existing shareholders maintain their statutory pre-emptive rights. The aggregate principal amount is divided into 23,340,289 convertible bonds in bearer form with a principal amount of 1.00 EUR each, which rank pari passu among themselves. The convertible bonds can be converted into bearer shares of common stock without par value (but with an arithmetic pro rata value of 1.00 EUR). These shares bear rights to full dividends for the financial year in which they are issued. The subscription price for the convertible bonds will be 1.00 EUR each and the subscription ratio is 15:7. The conversion period initially commences on 6 November 2013. The convertible bonds will mature on 23 March 2015 and bear interest of 3.00 % p. a. on their principal amount. At maturity, the convertible bonds will be subject to mandatory conversion into shares of the Company. Both measures described above require the Company to publish a Securities Prospectus, which is currently undergoing review and approval by Federal Financial Supervisory Authority BaFin. The Executive Board expects the approved Securities Prospectus will be published on the Company's web site on Friday 27 September 2013. In connection with the resolutions above, Gigaset AG has today entered into an Investor Agreement with Goldin Fund Pte. Ltd., a limited company incorporated in Singapore. This company is owned by the Hong Kong entrepreneur Mr. Pan Sutong, who holds a diversified portfolio of companies, including companies active in the consumer electronics business. Goldin Fund Pte. Ltd. intends to enter into a strategic cooperation with Gigaset group, to develop new market segments in consumer electronics which were previously not covered by Gigaset group. Under the Investor Agreement, Goldin Fund Pte. Ltd. has irrevocably committed to Gigaset AG, equinet Bank AG and Bankhaus Neelmeyer AG to acquire all remaining new shares and convertible bonds not subscribed by shareholders of the Company at the respective subscription price. This obligation is subject to the condition precedent that Goldin Fund Pte. Ltd. - acquiring such shares and convertible bonds not subscribed for by the shareholders of the Company after the capital increase and on the assumption the convertible bonds are being converted - will hold a minimum of 30 % in the voting rights in the Company ('Shareholding Condition'). Goldin Fund Pte. Ltd. has also undertaken to make an offer for the acquisition of all shares in the Company (takeover bid). In the case that the Shareholding Condition is not fulfilled, Goldin Fund Pte. Ltd. has the right to add minimum acceptance conditions to the takeover bid. According to the Investor Agreement, the price offered by Goldin Fund Pte. Ltd. during the takeover bid will be EUR 1.00 per Gigaset share. In addition, the Investor Agreement provides rules pertaining to further capital measures of Gigaset group companies to finance the establishment of a new business unit for tablet computers, smartphones and other mobile communications devices ('New Business'). Under these provisions, Goldin Fund Pte. Ltd. is, under certain circumstances (including the Shareholding Condition), obliged and entitled to participate in a capital increase which is to be resolved at a later stage, under exclusion of statutory pre-emptive rights of existing shareholders, and to acquire approximately 5.3 million new shares against payment of approximately EUR 5.3 million. The 5.3 million new shares will be composed of the remaining 262,286 shares from the Authorized Capital 2010 and of 5.1 million shares from the Authorized Capital 2013. In the case that the issue price for the new shares to be issued in this capital increase exceeds EUR 1.00. Goldin Fund Pte. Ltd. is not obliged to acquire these new shares. In addition, subject to the Shareholding Condition Goldin Fund Pte. Ltd. shall also contribute an amount of EUR 30 million to a subsidiary of Gigaset AG, which is planned to run the New Business. In return, Goldin Fund Pte. Ltd. shall receive preference shares in this subsidiary. Depending on the capital requirements of the subsidiary running the New Business, which will be jointly determined by Gigaset AG and Goldin Fund Pte. Ltd. at a later stage, Goldin Fund Pte. Ltd. has the right to contribute up to a further EUR 140 million to the subsidiary in return for receiving additional preference shares in this subsidiary. It is the intention that Goldin Fund Pte. Ltd., at a later stage and subject to separate capital increase decisions which have to be made during a Shareholder's Assembly of Gigaset AG, may contribute its preference shares to Gigaset AG in kind. The value of the preference shares to be contributed shall be, on the assumption that an impairment test on the contribution date is passed, the value of the contributions made by Goldin Fund Pte. Ltd. to the subsidiary as of the date of the contribution to the respective subsidiary. The issue price due for the new shares shall be EUR 1.00. The above plans - and thus the establishment of the New Business together - are also subject to the Shareholding Condition. Due to the two capital measures adopted today and subject to the occurrence of the conditions described herein, Gigaset AG will receive a minimum of approximately EUR 15.4 million and a maximum of EUR 42.9 million. The plans of the Company for the use of the proceeds is described in detail in the Securities Prospectus, which is currently undergoing review and approval by Federal Financial Supervisory Authority BaFin and will be published by the Company afterwards. Disclaimer: This document is for promotional purposes only and is not a securities prospectus. Interested investors should make their investment decision with respect to the securities mentioned in this document solely on the basis of information contained in a securities prospectus published by Gigaset AG in connection with the offering of these securities. Following its publication the securities prospectus will, be available free of charge at Gigaset AG, Hofmannstra�e 61, 81379 Munich, or at the company website (www.gigaset.ag). This document does not constitute an offer of securities for sale in the United States of America (USA) or in any jurisdiction in which such offer may be restricted. Securities mentioned in this document may be sold in the United States only with the prior registration, or an exemption from registration under the Securities Act of 1933, as amended from time to time. Gigaset AG does not intend to register the offer of the Securities in whole or in part in the United States or to execute a public offering of securities in the United States or elsewhere, except in Germany. Gigaset AG, Munich, is an internationally operating company in the area of communications technology. The Company is Europe's market leader in DECT telephones. Gigaset AG is listed on the Prime Standard of Deutsche Börse and so is subject to the very highest requirements for transparency. Its shares are traded on the Frankfurt Stock Exchange under the symbol 'GGS' (ISIN: DE0005156004). Learn more about Gigaset at www.gigaset.ag Contact: Gigaset AG Kerstin Diebenbusch, Investor Relations Stefan Zuber, Corporate Communications Phone: +49 (0)89 444456-937 Phone: +49 (0)89 444456-866 E-mail: info@gigaset.com E-mail: info.presse@gigaset.com 27.09.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Gigaset AG Hofmannstra�e 61 81379 München Germany Phone: +89444456937 Fax: +89444456930 E-mail: kerstin.diebenbusch@gigaset.com Internet: www.gigaset.com ISIN: DE0005156004 WKN: 515600 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Gigaset AG: Capital increase out of authorized
Top 10 Most Recent News Articles
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
NARUTO Card Game Set for June 2027 Global Launch
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
AI Drives Major Time Savings in Endoscopy Tech
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue ReadingTop 5 Most Recently Viewed Articles
Chart Industries Transitions to New Leadership in Upcoming Merger
Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...
Continue Reading
Understanding Debtors: Insights into Realkredit Danmark A/S
Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...
Continue Reading
Cryptocurrency Market Update: Bitcoin Droops under $59K with ETF Inflows Soaring
Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...
Continue Reading
Enhancing Specialized Care for ARFID Treatment with Emily Program
Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...
Continue Reading
Investigation of Alleged Securities Fraud at 3D Systems Unfolds
Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...
Continue Reading